Organization (Other)
Philips Healthcare
ClinicalTrials.gov lists Philips Healthcare as lead sponsor of 36 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
This page covers Philips Healthcare: 36 lead-sponsored trials and 0 legal-entity registrations. Part of KONINKLIJKE PHILIPS NV.
Disease areas (100)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leiomyoma | 6 |
| Myofibroma | 6 |
| Prostatic Neoplasms | 6 |
| Breast Neoplasms | 5 |
| Heart Failure | 5 |
Showing 5 of 100 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 6 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 7 |
| 2021 | 8 |
| 2020 | 6 |
| 2019 | 9 |
| 2018 | 9 |
| 2017 | 13 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: none of the 36 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 27% hit target (n=11) | 38% on time (n=8) |
Journals published in (150)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of respiratory and critical care medicine | 8 |
| Critical care (London, England) | 8 |
| Chest | 7 |
| Obstetrics and gynecology | 7 |
| American journal of obstetrics and gynecology | 6 |
Showing 5 of 150 journals.
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Bioaraba Health Research Institute | Co sponsors trial with | 1 |
| New York Presbyterian Hospital | Co sponsors trial with | 1 |
| MicroConstants | Co sponsors trial with | 1 |
| Innovative Analytics | Co sponsors trial with | 1 |
| Complexa, Inc. | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (130)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 130 events.
Biomarker capability evidence (52)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BTK | Trial collaborator | Named in trial inclusion criteria |
| CSF3 | Trial collaborator | Named in trial inclusion criteria |
| DLD | Trial collaborator | Named in trial inclusion criteria |
| DLD | Trial collaborator | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 52 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.